Is there a big difference in the effects of Pralsetinib and Serpatinib?

Platinib (Pralsetinib) and Selpatinib (Selpercatinib) are targeted therapeutic drugs targeting RET gene fusion mutations or rearrangements. They are mainly used to treat specific types of tumors such as non-small cell lung cancer (NSCLC) and thyroid cancer. Both drugs are selective RET inhibitors with high targeting and low non-specific toxicity. They are currently one of the important treatment options for patients with RET-positive tumors.

In terms of efficacy, the overall performance of platinib and serpatinib is similar. According to clinical trial data, the objective response rate of both in RETfusion-positive NSCLC patients (ORR) all exceeded 60%, and the progression-free survival (PFS) was also about one year. For RETmutated medullary thyroid carcinoma, both also showed strong tumor suppressor activity. Responses may vary between individual patients, but overall, there is little difference in the therapeutic effect between the two in the main indications.

However, there are certain differences in the spectrum of adverse reactions between the two. Common adverse reactions of serpatinib include hypertension, elevated transaminases, and prolongation of the QT interval, while platinib is more likely to cause hematological toxicities such as neutropenia and anemia. Therefore, when choosing a drug, doctors often make decisions based on the patient's underlying disease, tolerance, and potential risk factors. For example, patients with a history of heart disease may be more likely to be treated with platinib, while patients with hematologic disease may be better candidates for serpatinib.

In general, platinib and serpatinib have similar effects in treating RET positive tumors, and the difference in efficacy is not significant. The main selection basis is the individual characteristics of the patient and the controllability of side effects. With the accumulation of clinical experience and the continuous enrichment of real-world data, the application scope and optimization strategies of these two drugs will be further clarified, providing more precise treatment options for patients with RET fusion mutations.

Reference materials:https://gavreto.com/